Life Sciences & Chemistry

Are you a founder in the field of life science and chemistry and on the lookout for financing? At HTGF, we not only offer you investment know-how, but also understand your specific needs and provide you with the right expertise to support your business ideas. We leverage our tailored network to help you achieve success.

Many steps must be taken to become a successful start-up

Our Life Sciences & Chemistry team has the required start-up spirit! We have both entrepreneurial expertise and an understanding of science, medicine and practical applications. Having invested in over 200 life science and chemical companies since 2005, we know what really matters.

With our expertise and passion, we are at your side as a sparring partner from seed to exit – whether it be in the field of drug development and biotech, medtech and diagnostics, digital health, R&D tools or chemistry.

The right tools

We offer you the right tools to meet your individual challenges as a founder of a life sciences and chemical start-up:

We help you get started

  • Fast and flexible seed financing
  • Matching with co-investors from our international network
  • Communication on an equal footing
  • Inspiration and knowledge transfer

Let’s develop and grow together

  • Support in the acquisition of follow-up financing
  • Exchanges with founders and our partners from research, industry and SMEs
  • Close connection with cooperation partners

A shared path – from seed to exit

  • Support in finding the most suitable M&A advisors
  • Support in negotiations and due diligence
  • Assistance with company valuations and incentives
  • Transaction security from trade sale to IPO
  • Access to the HTGF network with many potential buyers

Who we are

What you can expect from us

  • From the very early stage to the exit, we support you as partners with our know-how and understanding of your needs.
  • We have an entrepreneurial spirit – many of us have founded our own companies and we have the necessary appetite for risk
  • We understand how financing works and can call on our network
  • We have backgrounds as scientists and know the pitfalls: manufacturing/CMC, regulatory affairs, market access, team growth, business development, etc.

The areas we invest in include:

  Pharma/biotech

  Medtech

  R&D tools

  Diagnostics

  Digital health

  Chemistry

Our Life Sciences & Chemistry Portfolio 

Let’s turn ideas into reality!

Societal challenges, such as diseases or advancing climate change, require innovative solutions. And this is why pioneering start-ups in the fields of life sciences and healthcare, chemistry, food and agricultural technology, and new materials are playing a crucial role.

Germany has the platform to continue launching successful high-tech start-ups:

  • Top-class research at universities and institutes
  • Close cooperation between industry and consumers
  • Transfer-enabling support

With your innovative start-up ideas, we can create sustainable and disruptive solutions together – what are we waiting for?

Looking to start a business? Contact our team here.

Is your pitch deck complete? Upload it here!

Topics that might interest you

Press
18. November 2024

Sedivention raises €800,000 in pre-seed funding for novel obesity therapy 

The medtech start-up is developing a device for a one-time, minimally invasive therapy for obesity. Sedivention has secured €800,000 in funding from High-Tech Gründerfonds (HTGF). The fresh capital will be used to advance the first preclinical studies and product development. Munich, 18 November 2024 – The German medical technology start-up Sedivention has received €800,000 in pre-seed funding from HTGF, one of the leading and most active early-stage investors in German
 
Press
14. November 2024


SRTD biotech secures seed financing: Side-effect free
RNA therapeutics active only in diseased cells

Jülich, Germany, 14 November 2024 – Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient RNA-based drugs that are active only in diseased cells. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have back
 
Press
13. November 2024

mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth

Berlin, Paris, 13 November 2024 – While Generative AI is creating a buzz across industries and remains in the early stages of the hype cycle, AI in radiology is no longer just a vision for the future. mediaire’s proven AI value is already happening in over 350 hospitals and clinics across Europe, where the German radiology innovator’s AI portfolio is transforming how radiologists work. With this success, mediaire has secured a €12 million European-led financing round, headed by lead
 
Press
12. November 2024

Zymofix secures €2 million to scale microbial solutions for sustainable agriculture and beyond

Additional financing to advance proprietary fermentation technology Looking to expand the team to support its rapid growth Rebranded from N-Fix to Zymofix – learn more at Zymofix.com Ghent, Belgium, 12 November 2024 – Zymofix, a pioneer in industrial biotechnology, has secured €2 million in funding led by High-Tech Gründerfonds (HTGF), with participation from The Nest Family Office and VP Capital. This strategic investment will fuel Zymofix’s efforts to scale its propriet
 
Press
31. October 2024

Berlin-Based Neurotech Startup Nuuron Secures Investment for the Development of a Digital Drug to Treat Alzheimer’s Disease

Activating the Memory System of the Brain with Software to Treat Alzheimer’s DiseaseNuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Nuuron’s algorithms produce ultra-high frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. This digital disease-modifying therapy uses the retina as interface into the brain and employs advanced VR and
 
Dräger GWA Hygiene BB
Blog
18. May 2022

GWA Hygiene and Dräger: From collaboration to investment

How does a company specialized in medical and safety technology with a more than 130-year history end up getting together with a six-year-old start-up? Common goals, collaboration on an equal footing and good partners are key aspects in this regard. That is at least according to Jens Altmann, President Business Unit Data Business at Dräger, and Tobias Gebhardt, CEO at GWA Hygiene. Dräger, a global corporation, recently invested in High-Tech Gründerfonds (HTGF) portfolio company GWA Hygien